BNET Industries

Seattle Genetics Inc. (SGEN) is in the Pharma Industry

Revenue: Dec 31 2007; $22.4M

Profit: Dec 31 2007; ($48.9M)

Market Cap: Nov 28 2008; $690.8M

Latest News and Analysis

Seattle Genetics to Present at the Oppenheimer Healthcare Conference

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Eric L. Dobmeier, Chief Business Officer, will present at the Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4, 2008, at 10:40 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. ...

Articles 2008-10-29
Seattle Genetics Presents on SGN-70 at American College of Rheumatology Meeting

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq: SGEN) today presented preclinical data on SGN-70 at the American College of Rheumatology ACR Annual Scientific Meeting in San Francisco, California. SGN-70 is a humanized monoclonal antibody targeting CD70 that is in development as a novel therapy for autoimmune diseases. Seattle Genetics is...

Articles 2008-10-28
Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs

BOTHELL, Wash. -- Seattle Genetics, Inc. (NASDAQ:SGEN), today announced data highlighting preclinical findings on two of its antibody-drug conjugate ADC programs, SGN-35 and SGN-19A, as well as research advances with its proprietary ADC technology. The data are being presented at the European Organization for Research and Treatment of Cancer-National Cancer...

Articles 2008-10-24
Seattle Genetics Reports Development Progress and Third Quarter 2008 Financial Results

-- Company Advancing Broad Pipeline of Cancer Therapies and Planning for Pivotal Trials of SGN-35 in 2009 -- -- Conference Call Today at 5:00 p.m. ET -- BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended...

Articles 2008-10-23
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2008 Financial Results on October 23, 2008

BOTHELL, Wash. -- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it will report its third quarter 2008 financial results on Thursday, October 23, 2008, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general...

Articles 2008-10-16

Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with Progenics

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate ADC collaboration agreement with Progenics Pharmaceuticals (Nasdaq:PGNX). The milestone was triggered by Progenics' initiation of a phase I clinical trial with its prostate-specific membrane antigen PSMA-targeted ADC for patients with hormone-refractory...

Articles 2008-10-15
Embryonic Heart Shows Strong Capacity to Regenerate

Healthy cells in an embryonic mouse heart can regenerate and replace diseased ones during development, but they may not be able to completely offset the later onset of cardiac problems, a new study shows. The findings, previously observed only in non-mammals, give researchers insight into how early onset cardiac...

Articles 2008-10-13
Seattle Genetics Adds to Senior Management Team

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointments of Elaine Waller, PharmD to Senior Vice President, Regulatory Affairs and Christopher Pawlowicz to Senior Vice President, Human Resources, as well as the promotion of Jonathan Drachman, M.D. to Vice President, Early Clinical Development. "A strong...

Articles 2008-09-30
Seattle Genetics to Present at the UBS Global Life Sciences Conference

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 2008 UBS Global Life Sciences Conference on Tuesday, September 23, 2008, at 10:00 a.m. Eastern Time. The conference is being held at the Grand Hyatt Hotel in...

Articles 2008-09-17
Seattle Genetics to Present at Upcoming Investor Conferences

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics, will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor...

Articles 2008-08-27
Seattle Genetics Initiates SGN-70 Phase I Clinical Trial

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase I clinical trial of SGN-70, a humanized monoclonal antibody targeting CD70 that is being developed as an investigational therapy for autoimmune diseases. The trial will assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy...

Articles 2008-07-31
Seattle Genetics Reports Second Quarter 2008 Financial Results

-- Conference call today at 5:00 p.m. ET -- BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2008. "We made strong progress across our product pipeline during the second quarter, highlighted by positive...

Articles 2008-07-22
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2008 Financial Results on July 22, 2008

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2008 financial results on Tuesday, July 22, 2008, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general...

Articles 2008-07-15
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Daiichi Sankyo

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into an exclusive, worldwide collaboration agreement with Daiichi Sankyo Co., Ltd. (TSE:4568) for the development of antibody-drug conjugates ADCs targeting a single antigen found on multiple types of solid tumors. Under the terms of the...

Articles 2008-07-08
VLST Corporation Appoints Internationally Recognized Researcher Paul J. Carter, Ph.D. as Chief Scientific Officer

SEATTLE -- VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, today announced that Paul J. Carter, Ph.D., a 20-year biotechnology research veteran, will join the Company as chief scientific officer and senior vice president of research and development. Dr....

Articles 2008-07-02
Weyerhaeuser Wins Best of Show at NIRI Seattle's Investor Communications Awards Gala

SEATTLE -- The Seattle Chapter of the National Investor Relations Institute NIRI announced today that Weyerhaeuser's 2007 annual report won "Best of Show" at the 2008 Investor Communications Awards Gala held June 26. Seattle Genetics won Best in Show among Biopharma/Healthcare entries, a new category this year. Twenty-one...

Articles 2008-06-27
Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing

BOTHELL, Wash. -- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate ADC collaboration with Genentech, Inc. The milestone was triggered by Genentech's filing of an Investigational New Drug IND application with the U.S. Food and Drug Administration FDA for an ADC utilizing...

Articles 2008-06-18
Seattle Genetics Announces SGN-35 Plenary Presentation at International Conference on Malignant Lymphoma

SEATTLE -- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that SGN-35 will be highlighted in an oral presentation during a plenary session on Saturday, June 7, 2008 at the International Conference on Malignant Lymphoma ICML being held in Lugano, Switzerland. In a phase I dose-escalation trial of SGN-35,...

Articles 2008-06-06
Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma

SEATTLE -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced final data from the phase I clinical trial of SGN-40 in patients with relapsed or refractory non-Hodgkin lymphoma. SGN-40 is a humanized monoclonal antibody being developed under a worldwide collaboration agreement with Genentech, Inc. Multiple objective responses were achieved and SGN-40 was...

Articles 2008-06-05
Seattle Genetics to Present at Upcoming Investor Conferences

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section. Needham & Company 7th Annual Biotechnology and Medical...

Articles 2008-06-04

Next »
page 1 of 1
« Previous

Incorporated: 1997
CEO: Dr. Clay B. Siegall Ph.D.

Seattle Genetics is a biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. As of Dec 31 2007, Co. had three lead clinical product candidates: SGN-40, which is in clinical trials for non-Hodgkin lymphoma and multiple myeloma; SGN-33, which is being developed for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and SGN-35, which is being developed for the treatment of Hodgkin lymphoma. Co.'s pipeline of product candidates is based upon two technologies: engineered monoclonal antibodies and monoclonal antibody-drug conjugates.